新型冠状病毒肺炎诊疗方案（试行第十版）
Diagnosis and treatment protocol for COVID-19 patients (Tentative 10th Version).
出版信息
Health Care Sci. 2023 Feb 23;2(1):10-24. doi: 10.1002/hcs2.36. eCollection 2023 Feb.
Abstract
To further improve the diagnosis and treatment of COVID-19, the National Health Commission of People's Republic of China and the National Administration of Traditional Chinese Medicine convened a group of experts to revise the relevant content of the Diagnosis and Treatment Protocol for COVID-19 Patients (Trial Version 9) and developed the Diagnosis and Treatment Protocol for COVID-19 Patients (Trial Version 10), summarizing the etiological characteristics, epidemiological characteristics, prevention, clinical features, diagnosis, clinical classification, population with high risk of severe/critical illnesses, early warning predictors for severe/critical illnesses, differential diagnosis, case identification and reporting, treatment, nursing, control of nosocomial infection in medical institutions, and discharge criteria for inpatients.
摘要
为进一步提高新型冠状病毒肺炎（COVID-19）的诊断和治疗水平，中华人民共和国国家卫生健康委员会和国家中医药管理局组织专家对《新型冠状病毒肺炎诊疗方案（试行第九版）》相关内容进行修订，形成了《新型冠状病毒肺炎诊疗方案（试行第十版）》，总结了病原学特点、流行病学特征、预防、临床特点、诊断、临床分型、重型/危重型高危人群、重型/危重型早期预警指标、鉴别诊断、病例发现与报告、治疗、护理、医疗机构内感染防控及住院患者出院标准等内容。
相似文献
1
Diagnosis and treatment protocol for COVID-19 patients (Tentative 10th Version).新型冠状病毒肺炎诊疗方案（试行第十版）
Health Care Sci. 2023 Feb 23;2(1):10-24. doi: 10.1002/hcs2.36. eCollection 2023 Feb.
2
Impact of Shenfu injection on a composite of organ dysfunction development in critically ill patients with coronavirus disease 2019 (COVID-19): A structured summary of a study protocol for a randomized controlled trial.参附注射液对 2019 冠状病毒病（COVID-19）危重症患者器官功能障碍发展复合结局的影响：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Aug 24;21(1):738. doi: 10.1186/s13063-020-04677-5.
3
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.新型冠状病毒病患者核酸检测由阴转阳的机制及临床转归和法匹拉韦的疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):488. doi: 10.1186/s13063-020-04430-y.
4
[Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus].[中草药及其活性成分干预人类冠状病毒的研究进展]
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1263-1271. doi: 10.19540/j.cnki.cjcmm.20200219.501.
5
[Analysis of the clinical characteristics and early warning model construction of severe/critical coronavirus disease 2019 patients].[新型冠状病毒肺炎重型/危重型患者临床特征分析及预警模型构建]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Apr;32(4):401-406. doi: 10.3760/cma.j.cn121430-20200325-00410.
6
Epidemiological and clinical characteristics of COVID-19 patients in Hengyang, Hunan Province, China.中国湖南省衡阳市新冠肺炎患者的流行病学和临床特征
World J Clin Cases. 2020 Jun 26;8(12):2554-2565. doi: 10.12998/wjcc.v8.i12.2554.
7
Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.中药麻杏石甘-苇茎汤治疗新型冠状病毒肺炎重型急性呼吸综合征患者的疗效：一项随机对照试验研究方案的结构化总结
Trials. 2020 Dec 23;21(1):1029. doi: 10.1186/s13063-020-04970-3.
8
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.一项由日本综合传染病管理（IMJEDI 研究-RCT）开展的多中心、随机对照临床试验，评估了汉方药加味抗感煎剂（kakkonto with shosaikotokakikyosekko）在缓解 COVID-19 轻症和中度患者症状和预防重症方面的作用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 2;21(1):827. doi: 10.1186/s13063-020-04746-9.
9
Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.安络化纤丸治疗 2019 年冠状病毒病重型患者的有效性和安全性：一项多中心、开放标签、随机对照研究的方案结构化总结：一项随机对照试验的研究方案。
Trials. 2020 Jun 8;21(1):495. doi: 10.1186/s13063-020-04399-8.
10
Current Snapshots on Stroke Prevention and Control and More Proactive National Strategies Against It in China.中国脑卒中防控现状及更积极的国家防控策略
J Cent Nerv Syst Dis. 2025 Apr 28;17:11795735251337605. doi: 10.1177/11795735251337605. eCollection 2025.
引用本文的文献
1
Real-World Analysis of Potential Drug-Drug Interactions with Nirmatrelvir/Ritonavir Based on the Hospital Prescription Analysis (HPA) Database in 9 Cities of China.基于中国9个城市医院处方分析（HPA）数据库的奈玛特韦/利托那韦潜在药物相互作用的真实世界分析
Infect Drug Resist. 2025 Aug 29;18:4539-4548. doi: 10.2147/IDR.S536758. eCollection 2025.
2
TIPE2 suppresses ferroptosis and pro-inflammatory polarization in macrophages triggered by SARS-CoV-2 spike protein.TIPE2抑制由SARS-CoV-2刺突蛋白触发的巨噬细胞铁死亡和促炎极化。
Sci Rep. 2025 Aug 18;15(1):30246. doi: 10.1038/s41598-025-14235-1.
3
Risk factor analysis and outcomes of heart transplant recipients infected by COVID-19.新冠病毒感染的心脏移植受者的危险因素分析及预后
Front Immunol. 2025 Jul 30;16:1597333. doi: 10.3389/fimmu.2025.1597333. eCollection 2025.
4
Assessment of cardiac dysfunction in COVID-19 patients using layer-specific strain echocardiography in short-axis and long-axis views.使用短轴和长轴视图的分层应变超声心动图评估COVID-19患者的心脏功能障碍。
BMC Cardiovasc Disord. 2025 Aug 13;25(1):602. doi: 10.1186/s12872-025-04971-7.
5
Convalescent plasma therapy for COVID-19 in patients with nasal catheter oxygen therapy.鼻导管吸氧的COVID-19患者的恢复期血浆治疗
J Thorac Dis. 2025 Jun 30;17(6):3532-3546. doi: 10.21037/jtd-2024-1991. Epub 2025 Jun 11.
6
Clinical Characteristics and Prognostic Factors of Severe COVID-19.重症新型冠状病毒肺炎的临床特征及预后因素
Infect Drug Resist. 2025 Jun 25;18:3117-3125. doi: 10.2147/IDR.S525970. eCollection 2025.
7
Clinical characteristics of 909 cases infected by Omicron BF.7 variant in Hohhot of China: A retrospective study.中国呼和浩特909例感染奥密克戎BF.7变异株病例的临床特征：一项回顾性研究
Medicine (Baltimore). 2025 Jun 20;104(25):e42794. doi: 10.1097/MD.0000000000042794.
8
Real-world practices of low-molecular-weight heparin for venous thromboembolism prophylaxis in patients hospitalized with COVID-19: a multicenter prospective study from China.低分子量肝素在COVID-19住院患者中预防静脉血栓栓塞的真实世界实践：一项来自中国的多中心前瞻性研究。
Thromb J. 2025 Jun 20;23(1):69. doi: 10.1186/s12959-025-00741-9.
9
The CD38HLA-DR T cells with activation and exhaustion characteristics as predictors of severity and mortality in COVID-19 patients.具有激活和耗竭特征的CD38⁺ HLA-DR⁺ T细胞作为COVID-19患者严重程度和死亡率的预测指标。
Front Immunol. 2025 Apr 30;16:1577803. doi: 10.3389/fimmu.2025.1577803. eCollection 2025.
10
Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID-19.西米普明瑞韦/利托那韦和奈玛特韦/利托那韦治疗中度至重度新型冠状病毒肺炎的有效性和安全性
Immun Inflamm Dis. 2025 Apr;13(4):e70174. doi: 10.1002/iid3.70174.
Zotero 插件